900814-48-4

900814-48-4 structure

Name: AVX 13616
Chemical Name: L-Leucine, N2-[2-[[(1S)-2'-(3-methylbutoxy)[1,1'-binaphthalen]-2-yl]oxy]acetyl]-D-lysyl-D-arginyl-, 3-methylbutyl ester, hydrochloride (1:2)
CAS Number: 900814-48-4
Molecular Formula: C₅₀H₇₃Cl₂N₇O₇
Molecular Weight: 955.06
Catalog: Biochemical Amino acids and their derivatives Leucine derivative
Create Date: 2018-06-20 18:50:11
Modify Date: 2024-01-09 11:00:58
AVX 13616 shows the potent in vivo antibacterial activity of Avexa’s lead antibacterial candidate; particularly against drug-resistant Staphylococcus pathogens.IC50 value: 2-4 ug/ml (MICs)Target: antibacterial agent AVX13616 was as active as mupirocin in a nasal decolonization model but required only a single application. The compounds are being developed for topical indications and/or wound infection/catheter-related infections. AVX13616 and other compounds showed broad spectrum antibacterial activity against a range of isolates with MICs of 2-4 micrograms per millilitre against S. aureus, coagulase negative staphylococci, enterococci, MRSA, VISA and VRSA. A single application of 5% (w/w) AVX13616 (approximately equimolar to 2% mupirocin) was as effective as 2% mupirocin administered twice a day for five days in nasal decolonisation of MRSA in mice.

Name	L-Leucine, N2-[2-[[(1S)-2'-(3-methylbutoxy)[1,1'-binaphthalen]-2-yl]oxy]acetyl]-D-lysyl-D-arginyl-, 3-methylbutyl ester, hydrochloride (1:2)
Synonyms	L-Leucine, N2-[[[(1S)-2'-(3-methylbutoxy)[1,1'-binaphthalen]-2-yl]oxy]acetyl]-D-lysyl-D-arginyl-, 3-methylbutyl ester, dihydrochloride Leucine, N-[2-[[2'-(3-methylbutoxy)[1,1'-binaphthalen]-2-yl]oxy]acetyl]-D-lysyl-D-arginyl-, 3-methylbutyl ester, hydrochloride (1:1) 3-Methylbutyl N-({[2'-(3-methylbutoxy)-1,1'-binaphthalen-2-yl]oxy}acetyl)-D-lysyl-D-arginylleucinate hydrochloride (1:1) AVX 13616

Description	AVX 13616 shows the potent in vivo antibacterial activity of Avexa’s lead antibacterial candidate; particularly against drug-resistant Staphylococcus pathogens.IC50 value: 2-4 ug/ml (MICs)Target: antibacterial agent AVX13616 was as active as mupirocin in a nasal decolonization model but required only a single application. The compounds are being developed for topical indications and/or wound infection/catheter-related infections. AVX13616 and other compounds showed broad spectrum antibacterial activity against a range of isolates with MICs of 2-4 micrograms per millilitre against S. aureus, coagulase negative staphylococci, enterococci, MRSA, VISA and VRSA. A single application of 5% (w/w) AVX13616 (approximately equimolar to 2% mupirocin) was as effective as 2% mupirocin administered twice a day for five days in nasal decolonisation of MRSA in mice.
Related Catalog	Signaling Pathways >> Anti-infection >> Bacterial Research Areas >> Infection
References	[1]. Avexa Presents Data from Apricitabine and Antibacterial Programs at two International Conferences